Non WHO Reference Material
Botulinum type F antitoxin, equine
NIBSC code: 01/506

Instructions for use
(Version 7.0, Dated 24/01/2014)

This material is not for in vitro diagnostic use.

1. INTENDED USE
This material is a freeze-dried residue of horse antiserum to Clostridium botulinum type F toxin. It is intended for calibration of the bioassay for botulinum type F antitoxin. The material may also be suitable to confirm serotype identity of botulinum type F toxin.

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNTAGE
This material is a candidate replacement for the 1st International Standard for botulinum type F antitoxin (BUSF). Full calibration has yet to be performed in collaborative studies. Preliminary tests at NIBSC have indicated 125 IU/ampoule by local flaccid paralysis assay relative to the 1st WHO International Standard (BUSF).

4. CONTENTS
Country of origin of biological material: United States.

This preparation contains the freeze-dried residue of 1.0 ml of horse plasma. The bulk material was donated in 1998 by the US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA. Horses were immunised with toxoid (pure neurotoxin from strain Langeland) then toxin (pure neurotoxin and complex from strain Langeland) and plasma collected after 95 weeks. (Langeland is a proteolytic type F strain.)

5. STORAGE
Unopened ampoules should be stored at -20°C. Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.

Clostridium botulinum antitoxins were established to define International Units for each type of antitoxin to be used in the control of therapeutic antitoxin preparations. Preparation and assay of the 1st International Standard for Clostridium botulinum types A, B, C, D and E antitoxins were described by Bowmer [1]. In 1964 the Statens Serum Institut (Copenhagen, Denmark) put forward a candidate type F antitoxin and in 1966 this material was accepted as the 1st type F WHO International Standard, BUSF [2]. This material, as replacement for BUSF, is intended for calibration of the bioassay for botulinum type F antitoxin. The material may also be suitable to confirm type F serotype identity.

8. STABILITY
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

Freeze-dried serum standards are expected to undergo negligible loss of activity during long term storage at the indicated storage temperature [3]. Once reconstituted, users should determine the stability of the material according to their own method of preparation, storage and use. Users who have data supporting any changes in the characteristics of this material are encouraged to contact NIBSC.

9. REFERENCES

10. ACKNOWLEDGEMENTS
We would like to thank USAMRIID for kindly donating this material.

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards: http://www.who.int/biologicals/en/
Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx
NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation’s title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance: Freeze dried powder</td>
</tr>
<tr>
<td>Corrosive: No</td>
</tr>
</tbody>
</table>

National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, EN6 3QG. T +44 (0)1707 641000, nibsc.org
WHO International Laboratory for Biological Standards, UK Official Medicines Control Laboratory

Page 1 of 2
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable:</td>
<td>Yes</td>
</tr>
<tr>
<td>Oxidising:</td>
<td>No</td>
</tr>
<tr>
<td>Hygroscopic:</td>
<td>Yes</td>
</tr>
<tr>
<td>Irritant:</td>
<td>No</td>
</tr>
<tr>
<td>Flammable:</td>
<td>No</td>
</tr>
<tr>
<td>Handling:</td>
<td>See caution, Section 2</td>
</tr>
<tr>
<td>Other (specify):</td>
<td>Contains equine plasma material</td>
</tr>
</tbody>
</table>

**Toxicological properties**

**Effects of inhalation:** Not established, avoid inhalation

**Effects of ingestion:** Not established, avoid ingestion

**Effects of skin absorption:** Not established, avoid contact with skin

**Suggested First Aid**

**Inhalation:** Seek medical advice

**Ingestion:** Seek medical advice

**Contact with eyes:** Wash with copious amounts of water. Seek medical advice

**Contact with skin:** Wash thoroughly with water.

**Action on Spillage and Method of Disposal**

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

---

15. **LIABILITY AND LOSS**

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. **INFORMATION FOR CUSTOMS USE ONLY**

**Country of origin for customs purposes**: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

**Net weight:** Approx. 100mg

**Toxicity Statement:** Non-toxic

**Veterinary certificate or other statement** if applicable.

**Attached**: No